Last reviewed · How we verify
Topiramate (drug)
Topiramate is a sulfamate-substituted monosaccharide that acts as a voltage-dependent sodium channel blocker and GABA receptor agonist.
Topiramate is a sulfamate-substituted monosaccharide that acts as a voltage-dependent sodium channel blocker and GABA receptor agonist. Used for Epilepsy, Migraine prevention.
At a glance
| Generic name | Topiramate (drug) |
|---|---|
| Also known as | Topamax |
| Sponsor | Erasmus Medical Center |
| Drug class | Sulfamate-substituted monosaccharide |
| Target | Voltage-dependent sodium channels, GABA receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Topiramate's mechanism of action involves blocking voltage-dependent sodium channels, which reduces the frequency of action potentials in neurons. Additionally, it acts as a GABA receptor agonist, enhancing the inhibitory effects of GABA on neuronal activity. This dual mechanism of action contributes to its anticonvulsant and neuroprotective effects.
Approved indications
- Epilepsy
- Migraine prevention
Common side effects
- Dizziness
- Headache
- Fatigue
- Nausea
- Weight loss
Key clinical trials
- Preoperative Weight Loss for Open Abdominal Wall Reconstruction (NA)
- Pharmacokinetics and Pharmacodynamics of Topiramate for Weight Loss in Youth: PHARMATOP (EARLY_PHASE1)
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study (PHASE4)
- Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity (PHASE2)
- Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder (PHASE4)
- Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery (PHASE4)
- Neurophysiological Effects of Medication Tapering During Treatment With Spinal Cord Stimulation
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topiramate (drug) CI brief — competitive landscape report
- Topiramate (drug) updates RSS · CI watch RSS
- Erasmus Medical Center portfolio CI